Publications by authors named "Alexander Currie"

Article Synopsis
  • The Phase 3 MELODY trial evaluated the effectiveness of nirsevimab in preventing RSV in children during their second RSV season.
  • Results showed that there was no increase in medically attended RSV lower respiratory infections or disease severity in children who received nirsevimab compared to those who received a placebo.
  • The clinical trial is registered at Clinicaltrials.gov under NCT03979313, confirming its scientific validity.
View Article and Find Full Text PDF

Excessive inflammation by phagocytes during infection is thought to promote lung function decline in CF patients. CFTR modulators have been shown to reduce colonization , however, their antifungal and anti-inflammatory mechanisms are unclear. Other treatments including azithromycin and acebilustat may dampen -induced inflammation due to their immunomodulatory properties.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the effectiveness and safety of a two-drug HIV treatment compared to a standard three-drug regimen in adults new to antiretroviral therapy (ART).
  • Both GEMINI-1 and GEMINI-2 trials were conducted in 21 countries, involving 1441 participants who were randomly assigned to either regimen to measure the proportion of individuals achieving adequate viral suppression at week 48.
  • Results indicated that the two-drug regimen was non-inferior to the three-drug regimen, with a significant percentage of participants on both treatments achieving viral loads below 50 copies per mL.
View Article and Find Full Text PDF

Mirogabalin, a selective voltage-dependent calcium channel α2δ ligand under development for treatment of neuropathic pain, may be coadministered with metformin in patients with type 2 diabetes mellitus who have diabetic peripheral neuropathic pain. A randomized, open-label, single-dose, 3-treatment, 3-period crossover study evaluated the pharmacokinetics (PK) and safety of mirogabalin and metformin upon coadministration. Eligible subjects received 3 treatments separated by a 7-day washout period: 1 oral dose of mirogabalin 15 mg; 1 oral dose of metformin 850 mg; and coadministration of mirogabalin 15 mg with metformin 850 mg.

View Article and Find Full Text PDF

Four randomized, double-blind, placebo-controlled, 4-period drug-drug interaction studies were conducted in healthy subjects to evaluate the pharmacokinetic and pharmacodynamic (PD) interactions between mirogabalin and commonly used central nervous system depressants. Mirogabalin or placebo was administered alone or with single-dose lorazepam, zolpidem, tramadol, ethanol, or interacting drug placebo. Safety was assessed and serial samples for pharmacokinetic parameters were collected for up to 48 hours postdose.

View Article and Find Full Text PDF

Background: Therapy with some HIV protease inhibitors (PI) contributes to insulin resistance and type 2 diabetes mellitus, by inhibition of insulin-sensitive glucose transporters. Atazanavir (ATV) is a new PI with substantially less in vitro effect on glucose transport than observed with other PI, including lopinavir (LPV) or ritonavir (RTV).

Methods: Randomized, double-blind, crossover study of the effect of 5 days of administering ATV, lopinavir/ritonavir (LPV/r) or placebo on insulin-stimulated glucose disposal in 30 healthy HIV-negative subjects.

View Article and Find Full Text PDF

The high-mobility-group A2 protein (HMGA2) plays important functional roles in transcriptional regulation, DNA replication and chromatin structure. In this study, the effect of histone deacetylase inhibition on the transcriptional activity of the Hmga2 gene was investigated in vivo both at the endogenous gene level and in a variety of cell lines using transiently transfected promoter constructs. Trichostatin A (TSA) repressed both transfected murine and human Hmga2 promoter constructs 3-8-fold in NIH3T3, F9 and HeLa cells.

View Article and Find Full Text PDF